Phase IIa trial of SPI 017 for the treatment of pain associated with spinal stenosis.

Trial Profile

Phase IIa trial of SPI 017 for the treatment of pain associated with spinal stenosis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2013

At a glance

  • Drugs SPI 017 (Primary)
  • Indications Musculoskeletal pain
  • Focus Adverse reactions
  • Sponsors Sucampo Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2013 This trial is expected to conclude in the fourth quarter of 2013, according to a Sucampo Pharmaceuticals media release.
    • 14 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top